Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Recurrent Ovarian or Primary Peritoneal Cancer
NCT00132067Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2005
- Primary completion
- Aug 2006
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoints: Progression-free survival rate at 6 months and Toxicity up to 5 years. Started Oct 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00132067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132067.